Search - tctmd.com

Displaying 541 - 560 of 2239

Sort: Relevancy | Date

More DAPT Duration Data, More Calls to Tailor to Individual Patients

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

November 05, 2021

Disrupt CAD III Shows Sustained Benefit for Lithotripsy at 1 Year

News Conference News TCT 2021

Disrupt CAD III Shows Sustained Benefit for Lithotripsy at 1 Year

November 05, 2021

Myocarditis After COVID-19 Vaccine: Data ‘Reassure’ More and More

News Conference News TCT 2021

Myocarditis After COVID-19 Vaccine: Data ‘Reassure’ More and More

November 04, 2021

iFR Matches FFR Through 5 Years: iFR-SWEDEHEART

News Conference News TCT 2021

iFR Matches FFR Through 5 Years: iFR-SWEDEHEART

November 04, 2021

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

News Conference News TCT 2021

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

November 04, 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

News Conference News TCT 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Yael L. Maxwell

November 04, 2021

FAVOR III China Adds Strength to Value of QFR-Guided PCI

News Conference News TCT 2021

FAVOR III China Adds Strength to Value of QFR-Guided PCI

November 04, 2021

FlowTriever Safe, Effective for Acute PE in Expanded FLASH Results

News Conference News TCT 2021

FlowTriever Safe, Effective for Acute PE in Expanded FLASH Results

November 03, 2021

Bioresorbable PFO/ASD Closure Device Shows Promise, but More Research Needed

News Daily News

Bioresorbable PFO/ASD Closure Device Shows Promise, but More Research Needed

Yael L. Maxwell

November 02, 2021

COVID-19: TCTMD’s Dispatch for November Week 1

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 1

November 01, 2021

Stimulants Linked to Early Risk of CV Events in Elderly

News Daily News

Stimulants Linked to Early Risk of CV Events in Elderly

Michael O'Riordan

October 25, 2021

COVID-19: TCTMD’s Dispatch for October Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 4

October 25, 2021

COVID-19: TCTMD’s Dispatch for October Week 3

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 3

October 18, 2021

FDA Issues New Guidance on Sodium Targets for Food Industry

News Daily News

FDA Issues New Guidance on Sodium Targets for Food Industry

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

October 12, 2021

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

October 11, 2021

Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis

News Conference News VIVA 2021

Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis

October 06, 2021

COVID-19: TCTMD’s Dispatch for October Week 1

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 1

October 04, 2021

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

News Features

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

September 28, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.